AMGN Maintained by Guggenheim -- Price Target Lowered to $378
Guggenheim maintained a Neutral rating on Amgen (AMGN) but lowered its price target from $388 to $378. Amgen's stock is currently trading at $417.57, which is 13.4% above its GF Value™ of $368.11, indicating overvaluation. The company has a GF Score™ of 85/100, showing strong financial health and profitability. Insider activity shows significant selling in the last three months.
How this was made
The 30-second read
Why it matters
The downgrade reflects concerns about overvaluation; investors may adjust positions accordingly.
Market read
Analyst target cuts can move stock price; this update provides fresh guidance for traders.
What to watch
Potential pipeline milestones or upcoming trial data could offset valuation concerns.
Background
Guggenheim's analyst Vamil Divan updated Amgen's rating on Oct 12, 2026, maintaining Neutral while reducing the price target from $388 to $378.
Ticker impact
Guggenheim lowered Amgen's price target to $378 and kept a Neutral rating, indicating a more cautious outlook.
likely downward pressure as investors price in the lower target
Target reduction signals valuation concerns; market may react with modest sell pressure.
Market effects
May prompt re‑evaluation of biotech sector valuations as analysts tighten targets.
Limited to US‑listed biotech investors.
Minimal global effect; primarily impacts Amgen shareholders.
Counterpoint
Some investors may view the target cut as an over‑reaction and see buying opportunity at current levels.
Key entities
- companyAmgen Inc.
US‑listed biotechnology firm (ticker AMGN).
- analyst_firmGuggenheim
Equity research firm providing the rating update.
